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ABSTRACT
Objective: The study was planned primarily to judge the effectiveness, safety, and adherence of the prescribed treatments in dermatophytosis along 
with the effect on the Quality of Life (QoL) of the affected individuals.
Methods: In this prospective observational study, spanning over 5 months, participants (dermatophytosis patients) were assessed at baseline and 
6 week-follow-up at study site. Information about their clinical presentation, QoL (Quality of Life) parameters, medication adherence, and adverse 
drug reaction (ADR) were entered in the Case Report Form (CRF) prepared by utilizing global standard tools such as 5D-itch scale, Dermatology Life 
Quality Index (DLQI), Medication Adherence Rating Scale (MARS), and PvPI-ADR reporting form respectively.
Results: Total 60 subjects (33 males and 27 females) had completed the study. Overall, tinea cruris (40%) was the most common variety followed by 
combination of tinea corporis and cruris (35%), tinea corporis (20%), and tinea incognito (3%). Pruritus was the predominant symptom. There was 
a significant (p<0.001) improvement of both 5D-itch & DLQI scores from baseline to follow-up stage (after 6 weeks). Treatment regimens were well 
tolerated (only eight subjects reported any adverse event such as gastric irritation and sedation). Medication adherence to the prescribed treatment 
was good; (mean MARS score 7.588±1.82). Mostly prescribed regimen was a combination of antifungal (oral plus topical) and antihistamine tablet 
(58/60, 96.66%). The most common drug combination was capsule itraconazole, luliconazole cream, and cetirizine or levocetirizine tablet with or 
without ketoconazole soap (35/60, 58.33%).
Conclusion: Prescribed treatment regimen for dermatophytosis was effective, tolerable, acceptable with high medication adherence and also 
improved the QoL of the study subjects.
Keywords: Dermatophytosis, 5D-itch, Quality of life, Medication adherence, Treatment outcome, DLQI, Effectiveness.
INTRODUCTION
Superficial fungal infections of hair, skin, and nails are the major cause 
of morbidity in India including West Bengal. Recently, dermatophytosis 
has emerged as an epidemic in many segments of India, posing a 
serious threat to our public health [1]. Dermatophytosis is a collective 
superficial fungal disease with a plethora of tinea manifestations, most 
frequently tinea cruris and tinea corporis. Trichophyton rubrum was 
reported as the leading fungal pathogen of tinea corporis and cruris 
in Rajasthan and Chennai whereas in Lucknow and Delhi,Trichophyton 
mentagrophytes and Microsporum audouinii were reported as 
predominant fungi. A recent publication from West Bengal had shown 
T. verrucosum, as the commonest causative organism thus displaying 
a varied and changing spectrum of the tinea infection over time [1,2]. 
Despite having a range of available anti-dermatophyte therapy, some 
treatment-related issues such as irrational use of antifungal agents, 
widespread use of cocktail antifungal-steroidal creams and suboptimal 
dose or duration of therapy often promote antifungal resistance and 
clinical failure. Other factors such as incorrect diagnosis, dressing 
pattern of the host including unhealthy lifestyle practices also provoke 
the recurrence of the disease [3-5].
While recalcitrant infections are becoming more and more prevalent, 
there is a relative paucity of literature revealing this changing scenario; 
hence, the present study.
Thus, the study was aimed to assess the overall effectiveness, tolerability, 
safety, and adherence to the treatment prescribed for dermatophytosis 
and its impact on the quality of life of the sufferers.
MATERIALS AND METHODS
Materials
This study was a self-responsive questionnaire based study, where 
standardized questionnaires were used for assessment of various 
parameters. For the assessment of clinical presentation, treatment 
outcome, QoL, tolerability, safety and medication adherence, we used 
5D-Pruritus scale (Elman et al.), clinician perceived 5-Point Likert scale, 
DLQI questionnaire (Finlay et al.), PvPI-ADR reporting form, and MARS 
scale (Thompson et al.), respectively [6-11]. Besides, prescription pattern 




This was a prospective observational single cohort study.
Study site and duration
This study was conducted at dermatology outpatient department 
(OPD) of a tertiary care teaching hospital, during November 2019 to 
© 2021 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons.org/
licenses/by/4.0/) DOI: http://dx.doi.org/10.22159/ajpcr.2021v14i9.39239. Journal homepage: https://innovareacademics.in/journals/index.php/ajpcr
Research Article
110
Asian J Pharm Clin Res, Vol 14, Issue 9, 2021, 109-112
 Mukherjee et al.
March, 2020. Ethics approval was obtained from the Clinical Research 
Ethics Committee of the institute [Ref: CREC-STM/2019-AS12].
Sample size
All consecutive patients attending 2 outpatient days a week, freshly-
diagnosed with dermatophytosis and having consented to take part in 
the study, were enrolled. Enrollment of study participants were done 
over one and half months starting from mid December 2019. Out of 
initially enrolled 114 study subjects, finally 60 subjects completed the 
follow-up visit after 6 weeks, the rest (54 subjects) did not turn up.
Methodology
Adult new patients of dermatophytosis (tinea infections of skin), 
clinically diagnosed and prescribed at the dermatology OPD were 
recruited as study subjects. After obtaining a written informed consent, 
study subjects were examined clinically and interviewed verbally. 
The diagnosis, treatment details, medication use history along with 
information on demographic and quality of life parameters were 
entered in the CRF and they were instructed to attend the OPD in the 
scheduled follow-up visit (after 6 weeks) as advised by the treating 
physician. In the follow-up visit, study subjects were again interviewed 
regarding their disease status, compliance of the medications, quality 
of life, treatment outcome etc. and data were entered in the CRF. In 
addition, physician’s assessment about disease status and prescription 
details had been documented in the CRF.
Parameters observed
•	 Demographic characteristics at baseline
•	 Clinical presentation (at baseline and follow-up) and treatment 
outcome by 5D itch score and physician perceived 5 point Likert 
score
•	 QoL status (at baseline and follow-up) by DLQI score
•	 Adherence or compliance of the received treatment by MARS score.
Statistical methods
Data were collected and entered manually into Microsoft Excel 2016 
and statistical analysis was done using SPSS version 20. Numerical 
data were expressed in Mean ± SD, categorical data in number 
(%) and correlation analysis was done by Pearson’s correlation 
coefficient. Distribution of the data was tested by prior test of normalcy 
(Kolmogorov–Smirnov Test).
RESULTS
Total 60 study subjects with dermatophytosis finally completed the 
study. Their demographic characteristics are depicted below (Table 1)
Regarding the treatment outcome, a significant reduction (p<0.01) of 
both 5D-itch (mean difference 7.467) and DLQI score (mean difference 
6.850) from baseline to follow-up stage had been observed. As per 
clinician perceived effectiveness status (5-Point Likert score) majority, 
that is, 36 (58.10%) appeared much better at follow-up stage after 
6 weeks. While DLQI score was significantly improved from baseline 
to follow-up, medication adherence had been found to be quite high 
(Mean±SD = 7.58±1.82), 34 (56.66%) have high adherence (where 
adherence level considered as ≥8 out of total MARS score) and 
26 (43.33%) shows poor adherence (< 8 out of total MARS score) but 
with minimum missed pill days (Mean±SD= 2.87±4.66) (Table 2 and 
Fig. 1).
To test the strength of association between patient reported pruritus 
(5D-itch) with both QoL (DLQI) and physician perceived 5-point Likert 
score as well as between MARS score with both Missed dose and 
5-Point Likert score, a correlation analysis (Pearson’s correlation) was 
performed (Table 3).
The reported adverse events (AE) were few (only 8 out of 60 subjects) 
such as gastric irritation, sleep disturbance with itraconazole and 
sedation with cetirizine, levocetirizine (Table 4).
Most commonly prescribed regimen for dermatophytosis was found as 
a combination of antifungal (oral plus topical) and antihistamine tablet 
(58/60, 96.66%). The most common drug combination was capsule 
itraconazole, luliconazole cream and cetirizine or levocetirizine tablet 
with or without ketoconazole soap (35/60, 58.33%). At follow-up visit, 
Table 2: Statistics of the outcome parameters
S. No. Variable n (%) Mean±SD p value
1. 5D-itch Score  
(at baseline)
17.63±2.93 0.000*
2. 5D-itch Score  
(at follow-up)
10.17±3.57




Much better but still 
present (4)
36 (58.10%)
Little bit better but still 
present (3)
17 (27.40%)
Unchanged (2) 0 (0%)
Getting worse (1) 3 (4.8%)
4. DLQI Score  
(at baseline)
12.68±3.47 0.000*
5. DLQI Score (at  
follow-up)
5.83±3.23
6. MARS Score 7.583±1.82
7. Missed dose(days) 2.87±4.66




n (%)=number of subjects (in percentage), SD=Standard deviation, *paired t 
test, Adherent: ≥8 of total MARS score n (%)=number of subjects  
(in percentage), SD=Standard deviation, *paired t test, Adherent: ≥8 of total 
MARS score
Table 3: Correlation analysis between different assessment 
parameters
Variables n p r**
5D-Itch score (baseline)
DLQI score (baseline) 60 0.000 0.502
5D-Itch score (follow-up)
DLQI score (follow-up) 60 0.000 0.694
5D-Itch diff (baseline-follow-up)
DLQI diff (baseline-follow-up) 60 0.000 0.531
5D-itch diff (baseline-follow-up)
5-point Likert (follow-up) 60 0.002 0.391
MARS score
Missed dose (day) 60 0.000 −0.613
MARS score
5-point Likert (at follow-up) 60 0.009 0.337
**Pearson’s correlation coefficient
Table 1: Demographic characteristics of the study subjects
Sample size (n)=60 n (%) Mean±SD
Age (in years) 33.03±15.20
Age categorization
<35 years 36 (60.00)







Tinea corporis +Tinea cruris 21(35.00)
Tinea incognito 3(5.00)
n (%)=Number of subjects ( percentage), SD=Standard deviation
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Medication adherence has an immense role on treatment effectiveness. 
An earlier study on medication adherence among patients with tinea 
pedis was found to have low adherence to oral antifungal agents 
in higher percentage (59.6%) [15]. But our study showed high 
adherence (≥80% of total MARS score) among majority of the study 
population (56.66%) indicating a good compliance toward prescribed 
medications. Noteworthy, even among non-adherent population, 
21% forgot to take medications for 2 days only whereas only 1.60% 
study subjects were non-adherent for more than 7 days (Fig. 1); so it 
reveals that adequate communication by health care providers fosters 
better treatment adherence and outcome (Table 3). Earlier study 
showed concomitant use of oral and topical antifungal agents increase 
medication adherence [15], the similar trend was also seen in the 
present study where a combination of antifungal (oral plus topical) and 
antihistamines was the predominantly prescribed regimen. Moreover, 
combination of oral itraconazole, luliconazole cream, and cetirizine 
or levocetirizine tablet with or without ketoconazole soap had been 
mostly prescribed, emerged as highly efficacious in this study. This is 
corroborating with a recently published study from the same region 
showing a changing pattern of infecting agent and drug sensitivity 
where itraconazole and luliconazole were found to be highly effective 
systemic and topical antifungals respectively against all Trichophyton 
species. [2] Earlier study on tolerability and safety of oral antifungals 
revealed common adverse events like nausea, rashes in 8–15% patients 
(griseofulvin), gastrointestinal or skin related (terbinafine) in 10.5% 
of population [16]. A favorable safety and tolerability profile of the 
treatment regimen was documented in the present study as noted 
above (Table 4).
Moreover, in most of the follow-up encounters (after 6 weeks as 
standard practice at study site), the primary prescriptions were 
repeated considering the favorable responses observed. Hence, 
corroborating with the changing pattern of the infecting organism and 
drug sensitivity, the standard treatment guideline and the procurement 
list of medicines should be updated at regular interval. The study had few 
limitations as well. Initially total 114 patients were recruited. However, 
in the follow-up all of them did not turn up. As it was a time bound 
(6 months) project, we could not recruit more subjects to adjust the loss 
to follow-up. Being a questionnaire based study; medication adherence 
was assessed by MARS (self-responsive tool) instead of any objective 
methods, but the subjective assessment of effectiveness (5D itch score) 
was corroborative with MARS score statistically, thus conforming to 
the patient’s perception about disease status. Recurrence of disease 
is very common in dermatophytosis often because of persistence of 
infection and emerging resistance to the antifungal agents, facilitated 
by improper selection and inadequate duration of treatment. So a study 
with long follow-up can only throw a light on these issues.
CONCLUSION
The treatment provided for dermatophytosis at study site (Dermatology 
OPD of the tertiary care hospital) mostly comprised a combination 
regimen of antifungal (both oral and topical) and antihistamines, which 
was effective enough to foster the clinical improvement of the disease as 
well as quality of life of the study subjects, and the prescribed treatment 
regimen appeared safe, tolerable, rational, and acceptable with a good 
compliance.
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we also studied the change of the initial regimen, altogether 30 (50%) of 
prescriptions remained unchanged and were repeated. However, when 
changed, it happened between oral itraconazole and terbinafine, among 
topical luliconazole, sertaconazole, amorolfine, etc. Only in one subject 
all medicines were discontinued in first follow-up. All others received 
a second prescription though the disease was controlled substantially 
in them.
DISCUSSION
In the present study, tinea cruris was the most common site of 
manifestation followed by mixed (T. corporis and cruris) variety, tinea 
corporis, and tinea incognito (Table 1) whereas earlier studies showed 
tinea corporis as a predominant site of infection [2,12]. Mostly young 
population were affected (mean age 33 years) as they spend hours 
mostly in outdoor activities, similar trend was also seen in earlier 
studies. Pruritus/itching was the prime complaint in all types of 
dermatophytosis. Although it tends to be a mild symptom, it severely 
affects the patient’s QoL. A previous study showed a positive correlation 
between itching and QoL parameter in dermatophytosis [13]. An 
appropriate treatment for dermatophytosis may have a great impact 
not only on clinical recovery but also in QoL improvement as evidenced 
by an earlier study [14]. In the present study, we also found a significant 
and moderately positive correlation between 5D-itch and DLQI at both 
baseline and 6 weeks post-treatment follow-up stage. Our study had 
shown a significant (p<0.01) improvement in the clinical parameter 
(mean 5D-itch score) and QoL parameter (mean DLQI score) from 
baseline to follow-up visit at 6 weeks post treatment. Moreover, 
correlation between changes of 5D-itch and DLQI score from baseline to 
follow-up visit also showed a moderately positive correlation (r=0.531, 
**p<0.01). So the prescribed treatment incurred a significant and 
favorable changes in both 5D-itch and DLQI score and thus was highly 
effective in dermatophytosis in this setting. As per clinician perceived 
effectiveness (by 5-Point Likert score), majority of study subjects 
(58.1%) appeared much improved clinically in follow-up visit pending 
complete recovery and thus had been asked to continue the treatment 
further beyond 6 weeks while 6.5% achieved complete recovery 
(Table 2). We also tested the effectiveness on the basis of both clinician’s 
judgment and patient’s perception. Hence, the correlation between 
5D-itch difference and 5-Point Likert score showed concordance 
(moderately positive correlation) of both patient’s perception and 





















Fig. 1: Bar chart of missed dose of subjects
Table 4: Adverse event profile of the received treatment









Gastric irritation 1 Itraconazole 200 1
Sedation 3 Cetirizine 10 1
Sedation 2 Levocetirizine 10 1
Sleep disturbance 1 Itraconazole 200 1
Nocturnal emission 1 Itraconazole 100 2
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